Ionis prepares olezarsen launch in severe hypertriglyceridemia pending FDA review
Ionis posts Q4 2025 revenue beat, strong TRYNGOLZA launch and DAWNZERA uptake, prepares olezarsen launch in severe hypertriglyceridemia pending FDA review
- TRYNGOLZA generated $50 million in Q4 and $108 million in 2025, reflecting stronger-than-expected initial commercialization.
- Management reports early DAWNZERA adoption and estimates DAWNZERA peak sales potential above $500 million.
- Ionis plans to be launch-ready by June for olezarsen in severe hypertriglyceridemia, pending FDA review.
- Q4 2025 revenue totaled $203.0M, down 11% year over year but above guidance and beating estimates.
- Company expects approximately 20% revenue growth in 2026 following its fourth quarter and full-year 2025 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.